PDOX Bibliography with Comments

A selection of published PDOX studies. These studies are available by request.

Search Bibliography :

  1. Murakami, T., DeLong, J., Eilber, F.C., Zhao, M., Zhang, Y., Zhang, N., Singh, A., Russell, T., Deng, S., Reynoso, J., Quan, C., Hiroshima, Y., Matsuyama, R., Chishima, T., Tanaka, K., Bouvet, M., Chawla, S., Endo, I., and Hoffman, R.M. Tumor-targeting Salmonella typhimurium A1-R in combination with doxorubicin eradicate soft tissue sarcoma in a patient-derived orthotopic xenograft PDOX model. Oncotarget 7, 12783-12790, 2016.
  2. The first PDOX model to correlate doxorubicin resistance in patients and PDOX in soft-tissue sarcoma.

  3. Kiyuna, T., Murakami, T., Tome, Y., Kawaguchi, K., Igarashi, K., Zhang, Y, Zhao, M., Li, Y., Bouvet, M., Kanaya, F., Singh, A., Dry, S., Eilber, F.C., and Hoffman, R.M. High efficacy of tumor-targeting Salmonella typhimurium A1-R on a doxorubicin- and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived orthotopic xenograft PDOX nude mouse model. Oncotarget 7, 33046-33054, 2016.
  4. The first PDOX model of follicular dendritic-cell sarcoma, also shows efficacy of bacterial efficacy.

  5. Yamamoto, M., Zhao, M., Hiroshima, Y., Zhang, Y., Shurell, E., Eilber, F.C., Bouvet, M., Noda, M.,Hoffman, R.M. Efficacy of tumor-targeting Salmonella typhimurium A1-R on a melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. PLoS One 11, e0160882, 2016.
  6. The first PDOX model of melanoma.

  7. Murakami, T., Singh, A.S., Kiyuna, T., Dry, S.M., Li, Y., James, A.W., Igarashi, K., Kawaguchi, K., DeLong, J.C., Zhang, Y., Hiroshima, Y., Russell, T., Eckardt, M.A., Yanagawa, J., Federman, N., Matsuyama, R., Chishima, T., Tanaka, K., Bouvet, M., Endo, I., Eilber, F.C., and Hoffman, R.M. Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing’s sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget 7, 47556-47564, 2016.
  8. The first PDOX model to demonstrate molecular targeting of Ewing’s sarcoma.

  9. Kawaguchi, K., Murakami, T., Chmielowski, B., Igarashi, K., Kiyuna, T., Unno, M., Nelson, S.D., Russell, T.A., Dry, S.M., Li, Y., Eilber, F.C., and Hoffman, R.M. Vemurafenib-resistant BRAF-V600E mutated melanoma is regressed by MEK targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model. Oncotarget 7, 71737-71743, 2016.
  10. Demonstrates PDOX is necessary to choose effective molecular targeting drugs for melanoma.

  11. Kawaguchi, K., Igarashi, K., Murakami, T., Chmiewloski, B., Kiyuna, T., Zhao, M., Zhang, Y., Singh, A., Unno, M., Nelson, S.D., Russell, T., Dry, S.M., Li, Y., Eilber, F.C., Hoffman, R.M. Tumor-targeting Salmonella typhimurium A1-R combined with Temozolomide regresses malignant melanoma with a BRAF-V600 mutation in a patient-derived orthotopic xenograft (PDOX) model. Oncotarget 7, 85929-85936, 2016.
  12. PDOX models demonstrates that bacterial therapy sensitizes melanoma to first line therapy.

  13. Murakami, T., Igarashi, K., Kawaguchi, K., Kiyuna, T., Zhang, Y., Zhao, M., Hiroshima, Y., Nelson, S.D., Dry, S.M., Li, Y., Yanagawa, J., Russell, T., Federman, N., Singh, A., Elliott, I., Matsuyama, R., Chishima, T., Tanaka, K., Endo, I., Eilber, F.C., and Hoffman, R.M. Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograph model resistant to a molecular-targeting drug. Oncotarget 8, 8035-8042, 2017.
  14. The first PDOX paper to show Salmonella typhimurium A1-R can regress a patient osteosarcoma resistant to a molecular targeting drug.

  15. Igarashi, K., Kawaguchi, K., Kiyuna, T., Murakami, T., Miwa, S., Nelson, S.D., Dry, S.M., Li, Y., Singh, A., Kimura, H., Hayashi, K., Yamamoto, N., Tsuchiya, H., Eilber, F.C., Hoffman, R.M. Patient-derived orthotopic xenograft (PDOX) mouse model of adult rhabdomyosarcoma invades and recurs after resection in contrast to the subcutaneous ectopic model. Cell Cycle 16, 91-94, 2017.
  16. The first PDOX paper to show that the orthotopic sarcoma model is aggressive and the subcutaneous model is benign.

  17. Kawaguchi, K., Igarashi, K., Chmielowski, B., Murakami, T., Kiyuna, T., Zhao, M., Zhang, Y., Nelson, S.D., Russell, T.A., Dry, S.M., Singh, A.S., Li, Y., Unno, M., Eilber, F.C., and Hoffman, R.M. Salmonella typhimurium A1-R targeting of a chemotherapy resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib-temozlomide. Cell Cycle, in press.
  18. Tumor-targeting Salmonella typhimurium A1-R enhances melanoma chemotherapy resistance in a PDOX model.

  19. Kawaguchi, K., Igarashi, K., Murakami, T., Zhao, M., Zhang, Y., Chmielowski, B., Kiyuna, T., Nelson, S.D., Russell, T.A., Dry, S.M., Li, Y., Unno, M., Eilber, F.C., and Hoffman, R.M. Tumor-targeting Salmonella typhimurium A1-R sensitizes melanoma with a BRAF-V600E mutation to vemurafenib in a patient-derived orthotopic xenograft (PDOX) nude mouse model. J. Cell. Biochem., Epub ahead of print. DOI: 10.1002/jcb.25886.
  20. Tumor-targeting Salmonella typhimurium A1-R sensitizes a melanoma PDOX to a molecular targeting drug.

  21. Murakami, T., Kiyuna, T., Kawaguchi, K., Igarashi, K., Singh A.S., Hiroshima, Y., Zhang Y., Zhao, M., Miyake, K., Nelson S.D., Dry, S.M., Li, Y., DeLong, J.C., Lwin, T.M., Chishima, T., Tanaka, K., Bouvet, M., Endo, I., Eilber, F.C., Hoffman, R.M. The irony of highly-effective bacterial therapy of a patient-derived mouse model of Ewing’s sarcoma, which was blocked by Ewing himself 80 years ago. Cell Cycle, in press.
  22. Salmonella typhimurium A1-R bacterial therapy is active against a Ewing’s sarcoma PDOX.

  23. Murakami, T., Li, S., Han, Q., Tan, Y., Kiyuna, T., Igarashi, K., Kawaguchi, K., Hwang, H.K., Miyaki, K., Singh, A.S., Nelson, S.D., Dry, S.M., Li, Y., Hiroshima, Y., Lwin, T.M., DeLong, J.C., Chishima, T., Tanaka, K.., Bouvet, M., Endo, I., Eilber, F.C., and Hoffman, R.M. Recombinant methioninase effectively targets a Ewing’s sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget 8, 35630-35638, 2017.
  24. PDOX efficacy for Ewing’s sarcoma.

  25. Igarashi, K., Kawaguchi, K., Murakami, T., Kiyuna, T., Miyake, K., Nelson, S.D., Dry, S.M., Li, Y., Yanagawa, J., Russell, T.A., Singh, A., Yamamoto, N., Hayashi, K., Kimura, H., Miwa, S., Tsuchiya, H., Eilber, F.C., Hoffman, R.M. Intra-arterial administration of tumor-targeting Salmonella typhimurium A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. Cell Cycle, in press.
  26. Intra-arterial chemotherapy regresses a cisplatinum-resistant osteosarcoma PDOX.

  27. Igarashi, K., Kawaguchi, K., Murakami, T., Kiyuna, T., Miyake, K., Singh, A., Nelson, S.D., Dry, S.M., Li, Y., Yamamoto, N., Hayashi, K., Kimura, H., Miwa, S., Tsuchiya, H., Eilber, F.C., Hoffman, R.M. High efficacy of pazopanib on an undifferentiated spindle-cell sarcoma resistant to first-line therapy is identified with a patient-derived orthotopic xenograft (PDOX) nude mouse model. J. Cell. Biochem., Epub ahead of print. DOI: 10.1002/jcb.25923
  28. PDOX efficacy for spindle-cell sarcoma.

  29. Igarashi, K., Kawaguchi, K., Kiyuna, T., Murakami, T., Miwa, S., Nelson, S.D., Dry, S.M., Li, Y., Singh, A., Kimura, H., Hayashi, K., Yamamoto, N., Tsuchiya, H., Eilber, F.C., Hoffman, R.M. Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget, Epub ahead of print. DOI: 10.18632/oncotrget.16548.
  30. PDOX efficacy for rhabdomyosarcoma.

  31. Kawaguchi, K., Igarashi, K., Chmielowski, B., Murakami, T., Kiyuna, T., Zhao, M., Zhang, Y., Nelson, S.D., Russell, T.A., Dry, S.M., Singh, A.S., Li, Y., Unno, M., Eilber, F.C., and Hoffman, R.M. Salmonella typhimurium A1-R targeting of a chemotherapy resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozlomide. Cell Cycle, Epub ahead of print. DOI: 10.1080/15384101.2017.1314420.
  32. PDOX efficacy for melanoma.

  33. Russell, T.A., Eckardt, M., Murakami, T., Eilliot, I., Kawaguchi, K., Kiyuna, T., Igarashi, K., Li, Y., Crompton, J., Graham, D.S., Dry, S.M., Bernthal, N., Yanagawa, J., Kalbasi, A., Federman, M., Chmielowski, B., Singh, A., Hoffman, R.M., Eilber, F.C. Clinical factors impacting the establishment of soft tissue sarcoma patient-derived orthotopic xenograft (PDOX): A UCLA sarcoma program prospective clinical trial. JCO Precision Oncology, in press.
  34. PDOX efficacy for soft tissue sarcoma in UCLA prospective clinical trial.

  35. Kawaguchi, K., Igarashi, K., Li, S., Han, Q., Tan, Y., Kiyuna, T., Miyake, Y., Murakami, T., Chmielowski, B., Nelson, S.D., Russell, T.A., Dry, S.M., Li, Y., Unno, M., Eilber, F.C., and Hoffman, R.M. Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma growth in a patient-derived orthotopic xenograft. Oncotarget, in press.
  36. PDOX efficacy for melanoma.

  37. Miyake, K., Murakami, T., Kiyuna, T., Igarashi, K., Kawaguchi, K., Li, Y., Singh, A.S., Dry, S.M., Eckardt, M.A., Hiroshima, Y., Momiyama, M., Matsuyama, R., Chishima, T., Endo, I., Eilber, F.C., Hoffman, R.M. Eribulin regresses a doxorubicin-resistant Ewing’s sarcoma with a FUS-ERG fusion and CDKN2A-deletion for the patient-derived orthotopic xenograft (PDOX) nude mouse model. J. Cell. Biochem., in press.
  38. PDOX efficacy for Ewing’s sarcoma.